Latest News

Ongoing Data Support Frontline Triplet in NSCLC
Ongoing Data Support Frontline Triplet in NSCLC

March 16th 2024

Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.

Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC
Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC

March 13th 2024

FDA Accepts Ensartinib Application in Non-Small Cell Lung Cancer
FDA Accepts Ensartinib Application in Non-Small Cell Lung Cancer

March 13th 2024

Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing

March 8th 2024

THIO Plus Cemiplimab Shows Promise in Non-Small Cell Lung Cancer
THIO Plus Cemiplimab Shows Promise in Non-Small Cell Lung Cancer

March 6th 2024

Video Series
Video Interviews
Podcasts

More News